Treats relapsing forms of multiple sclerosis (MS). ANDA 206921, held by Sandoz. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 206921 (Glatopa), held by Sandoz, was first approved by FDA on Feb 12, 2018, with 10 approved supplements and 0 published complete response letters.
Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 12, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatopa40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| Feb 12, 2026 | Supplement 33Labeling · Standard review | Approved | None posted |
| Mar 7, 2025 | Supplement 32Labeling · Standard review | Approved | None posted |
| Mar 19, 2024 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jul 5, 2023 | Supplement 28Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 26Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 12, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters